SER-109 is an investigational microbiome therapeutic made of purified Firmicutes spores.
The study was a phase 3 double-blind, randomized, placebo-controlled trial. The participants all had three or more C. difficile episodes and received SER-109 or a placebo. Of the 182 participants in the study, 12 percent of those who received SER-109 had recurring C. difficile after the treatment compared with 40 percent in the placebo group.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.